A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
Status:
Terminated
Trial end date:
2008-04-07
Target enrollment:
Participant gender:
Summary
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety
and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants
with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic
Lymphoma (SLL).